In Embodiment 8 of this disclosure are compounds of Formula I, or any one of Embodiments 1-7 or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 In Embodiment 9 of this disclosure are compounds of Formula I, or any one of Embodiments 1-8 or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is (1) phenyl unsubstituted or substituted with 1, 2, or 3 R 7 , (2) 5- or 6-membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with 1, 2, or 3 R 7 , (3) C 1-6 alkyl unsubstituted or mono-substituted, disubstituted, or trisubstituted with halogen, OH, CF 3 , CN, deuterium, or (C 3-6 )cycloalkyl, (4) (C 3-6 )cycloalkyl unsubstituted or optionally mono-substituted, disubstituted or trisubstituted with C 1-6 alkyl, halogen, OH, CF 3 , or CN, (5) (C 3-6 )alkylC(O)NH 2 , (6) 4- to 6-membered heterocyclyl containing 1 or 2 heteroatoms independently selected from N, O and S wherein the heterocyclyl is unsubstituted or substituted by 1, 2, or 3 R 7 , (7) CH 2 -heteroaryl unsubstituted or substituted by 1, 2, or 3 R 7 , (8) CH 2 -aryl unsubstituted or substituted by 1, 2, or 3 R 7 , (9) CH 2 -heterocyclyl unsubstituted or substituted by 1, 2, or 3 R 7 , (10) C(O) (C 1-6 )alkyl unsubstituted or substituted with 1, 2, or 3 R 7 , (11) C(O) (C 3-6 )cycloalkyl unsubstituted or substituted with 1, 2, or 3 R 7 , (12) C(O) (C 1-6 )heterocyclyl unsubstituted or substituted with 1, 2, or 3 R 7 , (13) C(O) aryl unsubstituted or substituted with 1, 2, or 3 R 7 , (14) SO 2 (C 1-6 )alkyl unsubstituted or substituted with 1, 2, or 3 R 7 (15) SO 2 (C 3-6 )cycloalkyl unsubstituted or substituted with 1, 2, or 3 R 7 , (16) SO 2 -aryl unsubstituted or substituted with 1, 2, or 3 R 7 , In Embodiment 10 of this disclosure are compounds of Formula I, or Embodiments 1-9, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is (1) phenyl unsubstituted or substituted with 1, 2, or 3 R 7 , (2) 5- or 6-membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N and S, wherein the heteroaryl is unsubstituted or substituted with 1 or 2 halogen, C 1-3 alkyl, or cyclopropyl, (3) C 1-6 alkyl unsubstituted or mono-substituted, disubstituted, or trisubstituted with halogen, OH, CF 3 , CN, deuterium, or (C 3-6 )cycloalkyl, (4) (C 3-6 )cycloalkyl unsubstituted or optionally mono-substituted, disubstituted or trisubstituted with halogen, C 1-6 alkyl, OC 1-3 haloalkyl, OH, CF 3 , or CN, (5) (C 3-6 )alkylC(O)NH 2 , (6) 4- to 6-membered heterocyclyl containing 1 or 2 heteroatoms independently selected from N, O and S wherein the heterocyclyl is unsubstituted or substituted with 1 or 2 substituents selected from CH 3 or oxo, (7) CH 2 -heteroaryl unsubstituted or substituted with 1 or 2 methyl substituents, (8) CH 2 -aryl, (9) CH 2 -heterocyclyl, (10) C(O) (C 1-6 )alkyl, (11) C(O) (C 3-6 )cycloalkyl, (12) C(O) (C 1-6 )heterocyclyl, (13) C(O) aryl, (14) SO 2 (C 1-6 )alkyl, or (15) SO 2 (C 3-6 )cycloalkyl
Orthostatic intolerance: Lightheaded upon standing, especially in warm environments or after a hot shower, can happen because the adrenaline/noradrenaline spikes arent regulated normally
See the compliance page for full terms
Discussing your medications and supplements with your healthcare provider is crucial
